The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 10, 2010, Pages 2231-2237

  Elias, Laura S ^a   Konzen, Daniele ^a   Krebs, Juliana M ^a   Zavascki, Alexandre P ^a,b  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Acinetobacter baumannii; Colistin; Mortality; Multidrug resistance; Pseudomonas aeruginosa; Treatment

Indexed keywords

ANTIBIOTIC AGENT; POLYMYXIN B;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; BACTEREMIA; CLINICAL ASSESSMENT; COHORT ANALYSIS; COMORBIDITY; DISEASE SEVERITY; DRUG SAFETY; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORTALITY; NEPHROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; SCORING SYSTEM; SEPSIS; SEPTIC SHOCK;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; BACTERIAL INFECTIONS; COHORT STUDIES; FEMALE; HOSPITAL MORTALITY; HUMANS; KIDNEY; KIDNEY DISEASES; MALE; MIDDLE AGED; POLYMYXIN B; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77957239326     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq285     Document Type: Article

References (20)

1. Zavascki AP, Goldani LZ, Li J et al. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother 2007; 60: 1206-15.
2. Zavascki AP, Carvalhaes CG, Picão RC et al. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Rev Anti Infect Ther 2010; 8: 71-93.
3. Dudhani RV, Turnidge JD, Coulthard K et al. Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob Agents Chemother 2010; 54: 1117-24.
4. Zavascki AP, Li J. Intravenous colistimethate for multidrug-resistant Gram-negative bacteria. Lancet Infect Dis 2008; 8: 403-5.
5. Kwa A, Kasiakou SK, Tam VH et al. Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Rev Anti Infect Ther 2007; 5: 811-21.
6. Tam VH, Schilling AN, Vo G et al. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005; 49: 3624-30.
7. Owen RJ, Li J, Nation RL et al. In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 2007; 59: 473-7.
8. Zavascki AP, Goldani LZ, Cao G et al. Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis 2008; 47: 1298-304.
9. Plachouras D, Karvanen M, Friberg LE et al. Population pharmacokinetic analysis of colistin methanesulphonate and colistin after intravenous administration in critically ill patients with Gram-negative bacterial infections. Antimicrob Agents Chemother 2009; 53: 3430-6.
10. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83.
11. Bone RC, Balk RA, Cerra FB et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-55.
12. Garner JS, Jarvis WR, Emori TG et al. CDC definitions for nosocomial infections. Am J Infect Control 1988; 16: 128-40.
13. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Eighteenth Informational Supplement M100-S18. CLSI, Wayne, PA, USA, 2008.
14. Falagas ME, Rafailidis PI, Ioannidou E et al. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents 2010; 35: 194-9.
15. Oliveira MS, Prado GV, Costa SF et al. Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity. Diagn Microbiol Infect Dis 2009; 65: 431-4.
16. Erbay A, Idil A, Gözel MG et al. Impact of early appropriate antimicrobial therapy on survival in Acinetobacter baumannii bloodstream infections. Int J Antimicrob Agents 2009; 34: 575-9.
17. Micek ST, Lloyd AE, Ritchie DJ et al. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005; 49: 1306-11.
18. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 2006; 10: R27.
19. Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). Clin Microbiol Infect 2006; 12: 315-21.
20. Zavascki AP, Li J, Nation RL et al. Stable polymyxin B susceptibility to Pseudomonas aeruginosa and Acinetobacter spp. despite persistent recovery of these organisms from respiratory secretions of patients with ventilator-associated pneumonia treated with this drug. J Clin Microbiol 2009; 47: 3064-5.